D. Boral Capital Reaffirms Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research report issued on Monday,Benzinga reports. They currently have a $34.00 price target on the stock.

Other analysts have also issued reports about the company. BTIG Research reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a research note on Monday, August 25th. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Wednesday, October 8th. Wall Street Zen lowered shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Zacks Research upgraded shares of NRx Pharmaceuticals to a “hold” rating in a research report on Wednesday, September 10th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of NRx Pharmaceuticals in a research report on Thursday, October 16th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, NRx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $34.75.

NRx Pharmaceuticals Stock Up 8.1%

NRXP opened at $2.28 on Monday. NRx Pharmaceuticals has a twelve month low of $1.13 and a twelve month high of $6.01. The company has a 50-day moving average price of $2.99 and a 200 day moving average price of $2.89. The company has a market cap of $45.17 million, a PE ratio of -0.97 and a beta of 1.76.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $6.83 million. As a group, sell-side analysts expect that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

Hedge Funds Weigh In On NRx Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Anson Funds Management LP increased its holdings in shares of NRx Pharmaceuticals by 26.2% during the 3rd quarter. Anson Funds Management LP now owns 2,025,104 shares of the company’s stock worth $6,683,000 after buying an additional 420,129 shares during the last quarter. Two Sigma Investments LP lifted its holdings in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after acquiring an additional 20,880 shares during the last quarter. Vanguard Group Inc. grew its position in NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after acquiring an additional 82,781 shares during the period. AdvisorShares Investments LLC grew its position in NRx Pharmaceuticals by 29.7% in the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after acquiring an additional 78,339 shares during the period. Finally, One Wealth Management Investment & Advisory Services LLC increased its stake in NRx Pharmaceuticals by 86.1% during the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after acquiring an additional 12,950 shares during the last quarter. 4.27% of the stock is currently owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.